An observational study in Multiple Sclerosis, sponsored by Lille Catholic University. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-26.
Sponsored by Lille Catholic University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Multiple Sclerosis by Lille Catholic University — 5 open to participants now, 5 under way, none of them phase 3. Multiple Sclerosis · Lille Catholic University.
Among the 18 studies in Multiple Sclerosis by Lille Catholic University, this one is one of 2 that started in 2022, is one of 7 observational ones, and was the 12th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →5 of the 18 studies in Multiple Sclerosis by Lille Catholic University are open now, in 1 country. Recruiting first, the newest first:
Lille Catholic University · Sites in France
Ages 18–55 · Healthy volunteers
Lille Catholic University · Sites in France
Ages 18–65
Lille Catholic University · Sites in France
Ages up to 18
Lille Catholic University
Ages 18–65
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 153 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 46 across the 11 interventional studies, 153 across the 7 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Lille Catholic University is the lead sponsor of 112 studies on the registry; 24 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Multiple Sclerosis by Lille Catholic University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to assess the role of sociocognitive and interpersonal factors in the therapeutic adherence of multiple sclerosis patients. This study will provide a better understanding of the socio-psychological issues associated with different types of non-adherence to treatment, and identify the risk factors and vulnerability of each patient.
Multiple sclerosis is a chronic and progressive disease that affects young adults (between 20 and 40 years old), impacting significantly the patients quality of life.
The adherence to therapy affects the long-term functional clinical course (lower risk of relapses, reduction in disability progression and quality of life). The non-adherence rate to therapy in multiple sclerosis is estimated at 40%. The main identified causes of non-adherence are: forgetting to take treatment and adverse effects of drugs.
Sociocognitive models as the Theory of Planned Behaviour (TPB) have been developed to help to understand and predict health-related behaviours. This model postulates that the intention to adopt a behaviour is one of the major determinants in the context of health. This intention comes from three independent elements :
Multiple sclerosis adherence to therapy studies have mainly focused on somatic variables (physical disability, illness duration, type of treatment) and some clinical variables (cognitive impairment, fatigue, depression). The few studies that have examined the multiple sclerosis therapeutic adherence determinants have mainly taken a one-dimensional perspective, such as perceived control.
In the FELSA-SEP study, the role of sociocognitive factors (norms and beliefs, perceived threat to disease and health behaviours) and interpersonal factors (social support, patient-doctor relationship) will be explored.
Persons with multiple sclerosis who will be recruited during a routine neurological consultation and who present eligibility criterion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with multiple sclerosis over 18 years old who have already started a long-term treatment and consent to participate to the study
Other: Study of the role of sociocognitive factors
Questionnaires
Therapeutic adherence evaluated by a Likert scale
This 19-item self-questionnaire provides 5 sub-scores corresponding to each of the sub-dimensions (Attitudes, Subjective norms, Perception of control, Behavioural intention and Behaviour) and an overall score (sum of the 5 sub-scores).
Time frame: 6 months
Perceived threat measured with a self-assessment form
The perceived threat will be measured with a self-assessment form using a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree). This 11-item self-questionnaire provides 2 sub-scores and an overall score (sum of the 2 sub-scores).
Time frame: 3 weeks
Perceived interpersonal relationships quality measure by the perceived social support questionnaire (QSSP)
* The QSSP is a 6 items questionnaire which assess availability and satisfaction with respect to perceived social support. * 4-Point ordinal Alliance Scale (11-items 4-PAS). This self-questionnaire concerns the patient's perception about the therapeutic alliance.
Time frame: 6 months
Perceived interpersonal relationships quality measure by the 4-Point ordinal Alliance Scale (11-items 4-PAS)
The 4-Point ordinal Alliance Scale (11-items 4-PAS). This self-questionnaire concerns the patient's feelings about the therapeutic alliance and includes eleven items, placing the patient on 5-point scale on : the patient's feeling about the doctor's ability to help him/her; his/her understanding of the symptoms of the illness; the psychological improvement felt; the adaptation to the doctor-patient relationship; the doctor's availability and competence; the clarity of the information given by the doctor and the understanding he/she shows; the doctor's desire of clinical improvement; the quality of the relationship and the understanding of psychological difficulties
Time frame: 6 months
Illness duration in days
In order to evaluate the vulnerability and protective factors related to somatic disease illness duration will be evaluated.
Time frame: 3 weeks
Handicap will be evaluated by the Expanded Disability Status Scale (EDSS)
In order to evaluate the vulnerability and protective factors related to somatic the handicap will be evaluated by the EDSS. The EDSS quantifies disability in eight Functional Systems (FS) by assigning a Functional System Score in each of these functional systems. The clinical meaning of each possible result goes from 0.0: Normal Neurological Exam to 10.0: Death
Time frame: 3 weeks
Relapses number
In order to evaluate the vulnerability and protective factors related to somatic disease number of relapses will be evaluated
Time frame: 3 weeks
Fatigue perceived through the FSS (Fatigue Severity Scale)
In order to evaluate the vulnerability and protective factors related to somatic disease fatigue will be evaluated. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.
Time frame: 3 weeks
Cognitive disorders through the SDMT (Symbol Digit Modalities Test)
In order to evaluate the vulnerability and protective factors related to somatic disease cognitive disorders will be evaluated The SDMT is a sign coding test that assesses attentional abilities (sustained attention and speed of processing information). Participants are required to use a coded key to match nine abstract symbols paired with numerical digits. The final score is the correct number of substitutions in 90 seconds, and scores range between 0 and 110.
Time frame: 3 weeks
Anxiety-depressive symptoms measured by the Hospital Anxiety and Depression Scale (HADS)
The vulnerability and protective factors linked to psychological functioning- as Anxiety-depressive symptoms will be determined. - Personality traits: Big Five Inventory-FR questionnaire (BFI-FR)
Time frame: 3 weeks
Personality traits measured by the Big Five Inventory-FR questionnaire (BFI-FR)
The vulnerability and protective factors linked to psychological functioning as personality traits will be determined. The Big Five personality traits is a suggested grouping for personality traits. The theory identifies five factors: * openness to experience (inventive/curious vs. consistent/cautious) * conscientiousness (efficient/organized vs. extravagant/careless) * extraversion (outgoing/energetic vs. solitary/reserved) * agreeableness (friendly/compassionate vs. challenging/callous) * neuroticism (sensitive/nervous vs. resilient/confident)
Time frame: 3 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2022 (actual). Primary completion is estimated for Jan 2025, 36 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 36 months is close to that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.